Odyssey Health, Inc. filed its Annual Report on Form 10-K for the fiscal year ended July 31, 2026, with the U.S. Securities and Exchange Commission, disclosing the company's financial condition, business activities, and ongoing product development efforts as of that date.

Key Highlights

  • Two product candidates in development: The company disclosed it is developing the CardioMap heart monitoring and screening device and the Save-A-Life choking rescue device, neither of which is currently being sold or marketed.
  • No current revenue: According to the filing, Odyssey is not currently selling or marketing any products, as its products require further development and FDA clearance or approval before U.S. sales can begin.
  • Shares outstanding: The filing reported 110,218,663 shares of common stock outstanding as of October 27, 2026.
  • Aggregate market value of non-affiliate equity: As of January 31, 2026, the aggregate market value of voting and non-voting common equity held by non-affiliates was reported as $6,195,975, based on a last sales price of $0.07 per share.
  • Smaller reporting company: The registrant identified itself as a non-accelerated filer and a smaller reporting company, and confirmed it is not a shell company.
  • OTC listing: The company's common stock ($0.001 par value) trades under the symbol ODYY on the OTC marketplace, registered under Section 12(g) of the Exchange Act.

Odyssey Health's Business Model and Development Stage as of July 31, 2026

Odyssey Health, Inc. (OTC:ODYY), a Nevada corporation formed in March 2014, describes its corporate mission as creating or acquiring assets, intellectual property, and technologies focused on medical products with superior clinical utility that address unmet medical needs. According to the filing, the company operates in one reportable segment encompassing all of its business activities.

The company disclosed that it plans to develop two technologies: the CardioMap heart monitoring and screening device and the Save-A-Life choking rescue device. The filing states that the company intends to engage third-party research and development firms, apply for trademarks and patents on proprietary products, and establish distribution or license agreements once regulatory clearances are obtained. The company noted that FDA clearance or approval is required before products can be marketed in the United States, and that additional country-specific clearances would be needed for international sales.

According to the filing, the company's growth strategy includes entering into distribution and license agreements with industry partners upon regulatory approval, requiring partners to pay an initial license fee plus royalties based on gross sales, and pursuing international license agreements. The filing notes that management has also chosen to focus on international growth because, "generally, such international license agreements provide a stronger path to revenue and earnings than purely domestic products." The filing contains forward-looking statements and notes that actual results may differ materially from those expressed, directing readers to the Risk Factors section.

What Was Disclosed

Odyssey Health filed its fiscal year 2026 annual report disclosing no current product sales, two medical devices under development pending FDA clearance, 110,218,663 shares outstanding as of October 27, 2026, and a non-affiliate market capitalization of $6,195,975 as of January 31, 2026.